These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11487275)

  • 1. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.
    Jones C; Nonni AV; Fulford L; Merrett S; Chaggar R; Eusebi V; Lakhani SR
    Br J Cancer; 2001 Aug; 85(3):422-7. PubMed ID: 11487275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
    Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
    BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases.
    Tsuda H; Takarabe T; Hasegawa F; Fukutomi T; Hirohashi S
    Am J Surg Pathol; 2000 Feb; 24(2):197-202. PubMed ID: 10680887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
    Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T
    J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
    Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
    Reis-Filho JS; Steele D; Di Palma S; Jones RL; Savage K; James M; Milanezi F; Schmitt FC; Ashworth A
    Mod Pathol; 2006 Feb; 19(2):307-19. PubMed ID: 16424897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.
    Fulford LG; Easton DF; Reis-Filho JS; Sofronis A; Gillett CE; Lakhani SR; Hanby A
    Histopathology; 2006 Jul; 49(1):22-34. PubMed ID: 16842243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of alpha-smooth muscle actin in infiltrating ductal carcinoma of the breast with productive fibrosis.
    Tamiolakis D; Papadopoulos N; Cheva A; Lambropoulou M; Kotini A; Jivannakis T; Simopoulos C
    Eur J Gynaecol Oncol; 2002; 23(5):469-71. PubMed ID: 12440829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin profiles of male breast cancers.
    Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
    Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.
    Fulford LG; Reis-Filho JS; Ryder K; Jones C; Gillett CE; Hanby A; Easton D; Lakhani SR
    Breast Cancer Res; 2007; 9(1):R4. PubMed ID: 17217540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7-year course of the disease.
    Surowiak P; Dziegiel P; Matkowski R; Kornafel J; Wojnar A; Zabe M
    Folia Histochem Cytobiol; 2002; 40(2):199-200. PubMed ID: 12056644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers.
    Leibl S; Gogg-Kammerer M; Sommersacher A; Denk H; Moinfar F
    Am J Surg Pathol; 2005 Mar; 29(3):347-53. PubMed ID: 15725803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
    Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
    Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
    Chiu K; Ionescu DN; Hayes M
    Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes.
    Jones C; Ford E; Gillett C; Ryder K; Merrett S; Reis-Filho JS; Fulford LG; Hanby A; Lakhani SR
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5988-97. PubMed ID: 15447982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.